Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Science 37 to Report Third Quarter 2022 Financial Results on November 10, 2022 By: Science 37, Inc. via GlobeNewswire November 01, 2022 at 07:55 AM EDT RESEARCH TRIANGLE PARK, N.C., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™ today announced it will report third quarter 2022 financial results after the market closes on Thursday, November 10, 2022. Company management will host a corresponding conference call on Friday, November 11, 2022, at 8:30 a.m. Eastern Time. The conference call can be accessed by registering online for dial-in information or via live audio webcast at: https://investors.science37.com/news-events/events-presentations. Participants interested in dialing in to the conference call are requested to register a day in advance or at a minimum 15 minutes before the start of the call to obtain a unique pin for the call. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days. About Science 37 Science 37 Holdings, Inc.’s (Nasdaq: SNCE) mission is to enable universal access to clinical research—making it easier for patients and providers to participate from anywhere and helping to accelerate the development of treatments that impact patient lives. As a pioneer of decentralized clinical trials, the Science 37 l Operating System (OS) supports today’s more agile clinical research designs with its full-stack, end-to-end technology platform and centralized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, provider communities, and data and devices. Configurable to enable almost any study type, the Science 37 OS enables up to 21x faster enrollment, 28% better retention, and 3x more diverse patient population with industry-leading workflow orchestration, evidence generation, and data harmonization. For more information, visit https://www.science37.com. Contacts: MEDIA INQUIRIES:Drew BustosScience 37Phone: (610) 417-6953Email: pr@science37.com INVESTOR RELATIONS:Steve HalperManaging DirectorLifeSci AdvisorsPhone: (646) 876-6455Email: shalper@lifesciadvisors.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Science 37 to Report Third Quarter 2022 Financial Results on November 10, 2022 By: Science 37, Inc. via GlobeNewswire November 01, 2022 at 07:55 AM EDT RESEARCH TRIANGLE PARK, N.C., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™ today announced it will report third quarter 2022 financial results after the market closes on Thursday, November 10, 2022. Company management will host a corresponding conference call on Friday, November 11, 2022, at 8:30 a.m. Eastern Time. The conference call can be accessed by registering online for dial-in information or via live audio webcast at: https://investors.science37.com/news-events/events-presentations. Participants interested in dialing in to the conference call are requested to register a day in advance or at a minimum 15 minutes before the start of the call to obtain a unique pin for the call. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days. About Science 37 Science 37 Holdings, Inc.’s (Nasdaq: SNCE) mission is to enable universal access to clinical research—making it easier for patients and providers to participate from anywhere and helping to accelerate the development of treatments that impact patient lives. As a pioneer of decentralized clinical trials, the Science 37 l Operating System (OS) supports today’s more agile clinical research designs with its full-stack, end-to-end technology platform and centralized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, provider communities, and data and devices. Configurable to enable almost any study type, the Science 37 OS enables up to 21x faster enrollment, 28% better retention, and 3x more diverse patient population with industry-leading workflow orchestration, evidence generation, and data harmonization. For more information, visit https://www.science37.com. Contacts: MEDIA INQUIRIES:Drew BustosScience 37Phone: (610) 417-6953Email: pr@science37.com INVESTOR RELATIONS:Steve HalperManaging DirectorLifeSci AdvisorsPhone: (646) 876-6455Email: shalper@lifesciadvisors.com
RESEARCH TRIANGLE PARK, N.C., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™ today announced it will report third quarter 2022 financial results after the market closes on Thursday, November 10, 2022. Company management will host a corresponding conference call on Friday, November 11, 2022, at 8:30 a.m. Eastern Time. The conference call can be accessed by registering online for dial-in information or via live audio webcast at: https://investors.science37.com/news-events/events-presentations. Participants interested in dialing in to the conference call are requested to register a day in advance or at a minimum 15 minutes before the start of the call to obtain a unique pin for the call. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days. About Science 37 Science 37 Holdings, Inc.’s (Nasdaq: SNCE) mission is to enable universal access to clinical research—making it easier for patients and providers to participate from anywhere and helping to accelerate the development of treatments that impact patient lives. As a pioneer of decentralized clinical trials, the Science 37 l Operating System (OS) supports today’s more agile clinical research designs with its full-stack, end-to-end technology platform and centralized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, provider communities, and data and devices. Configurable to enable almost any study type, the Science 37 OS enables up to 21x faster enrollment, 28% better retention, and 3x more diverse patient population with industry-leading workflow orchestration, evidence generation, and data harmonization. For more information, visit https://www.science37.com. Contacts: MEDIA INQUIRIES:Drew BustosScience 37Phone: (610) 417-6953Email: pr@science37.com INVESTOR RELATIONS:Steve HalperManaging DirectorLifeSci AdvisorsPhone: (646) 876-6455Email: shalper@lifesciadvisors.com
